NMP22 and surveillance for recurrent bladder cancer [8]

JAMA

Volumn 296, Issue 1, 2006, Pages 44-45

  Wilson, Chad T ^a  

^a VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEAR MATRIX PROTEIN 22; NUCLEAR PROTEIN; TUMOR MARKER;

BLADDER CANCER; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RECURRENCE; CLINICAL FEATURE; DIAGNOSTIC TEST; FALSE POSITIVE RESULT; HUMAN; LETTER; PREVALENCE; PRIORITY JOURNAL; PROTEIN DETERMINATION; REPEAT PROCEDURE; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; BLADDER TUMOR; NOTE; TUMOR RECURRENCE; URINE;

HUMANS; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PROTEINS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 33745616148     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.296.1.44-b     Document Type: Letter

References (4)

1. Grossman HB, Soloway M, Messing E, et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA. 2006;295:299-305.
2. Jaeschke R, Guyatt GH, Sackett DL; Evidence-Based Medicine Working Group. How to use an article about a diagnostic test, B: what are the results and will they help me in caring for my patients? JAMA. 1994;271:703-707.
3. National Comprehensive Cancer Network. Bladder Cancer: Including Upper Tract Tumors and Urothelial Carcinoma of the Prostate. Version 1.2006. Jenkintown, Pa: National Comprehensive Cancer Network; November 9, 2005. Clinical Practice Guidelines in Oncology series.
4. Schrag D, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB. Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst. 2003;95:588-597.